Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 in FGFR-altered advanced tumors (MATCH Subprotocol W)
NCT04439240Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fexagratinib in malignant solid neoplasm, lymphoma, hematopoietic and lymphoid cell neoplasm, plasma cell myeloma (MM), sponsored by National Cancer Institute. Started May 2016; status: completed.
02
Drugs
fexagratinib
03
Conditions
malignant solid neoplasmlymphomahematopoietic and lymphoid cell neoplasmplasma cell myeloma (MM)
Beyond the preview
Go deeper on NCT04439240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439240.